{"title":"Lipid Profile Differences in Monomeric Hyperprolactinemia, Macroprolactinemia, and Healthy Controls: A Comparative Analysis.","authors":"Sami Bahçebaşı, Ferhat Gökay, Yasin Şimşek","doi":"10.1159/000547540","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to investigate the effects of different prolactin isoforms - specifically macroprolactin and monomeric prolactin - on lipid metabolism across various subtypes of hyperprolactinemia.</p><p><strong>Methods: </strong>A total of 166 adults were retrospectively analyzed and categorized into macroprolactinemia, gray zone, and monomeric hyperprolactinemia (further subdivided into prolactinoma and idiopathic groups), along with a healthy control group. Lipid parameters, including total cholesterol, lipoprotein cholesterol (LDL), HDL, triglycerides, and non-HDL cholesterol, were compared among groups. Statistical analyses were adjusted for age and body mass index (BMI).</p><p><strong>Results: </strong>Patients with prolactinoma, idiopathic hyperprolactinemia, and those in the gray zone exhibited significantly elevated total cholesterol, LDL, and non-HDL cholesterol levels compared to healthy controls (p < 0.05). There were no significant differences in lipid profiles between the macroprolactinemia group and either the healthy controls or the monomeric hyperprolactinemia groups. Serum prolactin concentrations positively correlated with LDL, triglycerides, and non-HDL cholesterol, whereas macroprolactin recovery rates showed no such associations.</p><p><strong>Conclusion: </strong>Monomeric hyperprolactinemia - particularly in prolactinoma - is associated with dyslipidemia and potentially increased cardiovascular risk. In contrast, macroprolactinemia appears metabolically inactive or may represent an intermediate metabolic state. Differentiating prolactin isoforms are crucial for accurate clinical evaluation and appropriate metabolic risk assessment in patients with hyperprolactinemia.</p>","PeriodicalId":19117,"journal":{"name":"Neuroendocrinology","volume":" ","pages":"719-729"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroendocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547540","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: This study aimed to investigate the effects of different prolactin isoforms - specifically macroprolactin and monomeric prolactin - on lipid metabolism across various subtypes of hyperprolactinemia.
Methods: A total of 166 adults were retrospectively analyzed and categorized into macroprolactinemia, gray zone, and monomeric hyperprolactinemia (further subdivided into prolactinoma and idiopathic groups), along with a healthy control group. Lipid parameters, including total cholesterol, lipoprotein cholesterol (LDL), HDL, triglycerides, and non-HDL cholesterol, were compared among groups. Statistical analyses were adjusted for age and body mass index (BMI).
Results: Patients with prolactinoma, idiopathic hyperprolactinemia, and those in the gray zone exhibited significantly elevated total cholesterol, LDL, and non-HDL cholesterol levels compared to healthy controls (p < 0.05). There were no significant differences in lipid profiles between the macroprolactinemia group and either the healthy controls or the monomeric hyperprolactinemia groups. Serum prolactin concentrations positively correlated with LDL, triglycerides, and non-HDL cholesterol, whereas macroprolactin recovery rates showed no such associations.
Conclusion: Monomeric hyperprolactinemia - particularly in prolactinoma - is associated with dyslipidemia and potentially increased cardiovascular risk. In contrast, macroprolactinemia appears metabolically inactive or may represent an intermediate metabolic state. Differentiating prolactin isoforms are crucial for accurate clinical evaluation and appropriate metabolic risk assessment in patients with hyperprolactinemia.
期刊介绍:
''Neuroendocrinology'' publishes papers reporting original research in basic and clinical neuroendocrinology. The journal explores the complex interactions between neuronal networks and endocrine glands (in some instances also immunecells) in both central and peripheral nervous systems. Original contributions cover all aspects of the field, from molecular and cellular neuroendocrinology, physiology, pharmacology, and the neuroanatomy of neuroendocrine systems to neuroendocrine correlates of behaviour, clinical neuroendocrinology and neuroendocrine cancers. Readers also benefit from reviews by noted experts, which highlight especially active areas of current research, and special focus editions of topical interest.